A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause

Abstract

Understanding the role of both menopausal hormone therapy (MHT) along with non-hormonal options for the treatment of vasomotor symptoms, sleep disruption, and genitourinary symptoms after menopause is critical to the health of women during middle and later life. Recent updates to the evidence for the treatment of menopausal symptoms pertaining to both hormonal and non-hormonal therapies as well as updated guidance from specialty societies can help guide clinicians in their treatment of women going through natural menopause or with estrogen deficiencies due to primary ovarian insufficiency or induced menopause from surgery or medications. The objective of this narrative review is to provide clinicians with an overview of MHT for the use of menopausal symptoms in women, incorporating updated primary evidence for risk versus benefit profiles, recent specialty society recommendations, and alternative, non-hormonal options. In this review, we summarize literature on the use of MHT for menopause-related symptomatology including options for formulations and dosages of MHT, non-hormonal treatment options, and the risk–benefit profile of MHT including long-term health consequences (eg, cardiovascular disease, cognitive decline, venous thromboembolism, and fracture risk). Finally, we highlight areas in which future research is needed to advance care of women after menopause. In summary, both hormonal (MHT) and non-hormonal options exist to treat symptoms of menopause. There is strong evidence for safety and effectiveness of MHT for the treatment of vasomotor symptoms among women who are less than 60 years of age, less than 10 years since menopause, and without significant cardiometabolic comorbidities. For others, treatment with hormonal versus non-hormonal therapies can be considered based on individual risk profiles, as well as other factors such as drug formulation, therapeutic goals, and symptom severity.

Gynecologic Care of Black Breast Cancer Survivors

“…As this is contraindicated in breast cancer, other therapies should be explored. Selective serotonin reuptake inhibitors (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI) (such as venlafaxine), gabapentin, clonidine, and oxybutynin are commonly used non-hormonal options [ 83 ] for breast cancer survivors and can be trialed through shared-decision making and discussion of side effects. As of 2023, fezolinetant (Veozah) is a neurokinin 3 receptor antagonist approved by the U.S. Food and Drug Administration for the treatment of moderate to severe hot flashes [ 84 ].…”

The Menopausal Transition: Is the Hair Follicle “Going through Menopause”?

“…In the last few decades, a large number of randomized studies [9][10][11] on the "menopausal transition" have given us a clear chronology of the hormonal changes, and have provided us with a view of the reproductive and hormonal events that accompany the process [12,13].…”

Breast cancer survivals and hormone therapy: estrogen and melatonin

“…Some breast cancer survivors experience hot flashes without improvement when treated by the non-hormonal drugs, mainly serotonin reuptake inhibitors, as well as the inhibitors of reuptake of noradrenaline and serotonin and other substances 9 . It is a great concern to alleviate these symptoms, which affect sleep patterns, professional activities, and quality of life 1 , 2 .…”